pegylated epoetin alfa (YPEG-rhEPO)
/ BioGeneric Pharma, Xiamen Amoytop Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 16, 2022
A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease
(clinicaltrials.gov)
- P2 | N=60 | Completed | Sponsor: Xiamen Amoytop Biotech Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Jun 2022 ➔ Jan 2022 | Trial primary completion date: Jun 2022 ➔ Jan 2022
Trial completion • Trial completion date • Trial primary completion date • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease
May 13, 2021
A Phase 2 Trial of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease
(clinicaltrials.gov)
- P2; N=60; Recruiting; Sponsor: Xiamen Amoytop Biotech Co., Ltd.
Clinical • New P2 trial • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease
1 to 2
Of
2
Go to page
1